Return to Listing

3 result(s) for Paraplatin

PI Name Protocol # Title
Kathleen Kemmer IRB00011351 A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Jeremy Cetnar IRB00011845 A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-LI Antibody) Compared with A Platinum Agent (Cisplatin or Carboplatin) in Combination with either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naïve Patients Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Jeremy Cetnar IRB00011851 A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF MPDL3280A (ANTI PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN + PACLITAXEL OR MPDL3280A IN COMBINATION WITH CARBOPLATIN + NAB-PACLITAXEL VERSUS CARBOPLATIN + NAB-PACLITAXEL IN CHEMOTHERAPY NAÏVE PATIENTS WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080